- Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drugAvalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public…Endpoints · 3mo ago↗ source
- Sanofi posts upbeat sales as R&D pressure builds<figure><div><img src="https://imgproxy.divecdn.com/4sV6C1TzSj2YZ2rz0W5-EST8xmsio5JNKmZoYu-be_8/g:nowe:0:87/c:520:294/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…BioPharma Dive · 3mo ago↗ source
- Revolution drug shows promise in early pancreatic cancer<p>The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.</p>